Study overview
Niktimvo was studied in 79 people who had received a stem cell transplant, received at least 2 prior treatments for chronic graft-versus-host disease (GVHD), and weighed at least 88.2 pounds (40 kg).
of people (59 out of 79)
experienced some improvement in their chronic GVHD
In the clinical trial, all people who saw improvement achieved a partial response, meaning they saw improvement in at least one affected area without worsening signs or symptoms in other areas.
Niktimvo was studied in people with multi-organ disease
Eyes
Mouth
Esophagus
Lungs
Liver
Digestive tract
Joints/muscles
Skin
The median time to first response was 1.5 months (6 weeks)
The time to first response ranged from 4 weeks to 22 weeks.
of people (44 out of 79)
reported being less bothered by their chronic GVHD symptoms in an exploratory analysis of the study
This was measured using a patient questionnaire called the modified Lee Symptom Scale.
Helpful words to know
Exploratory analysis: An analysis that looks at additional information from the study to understand people’s experiences. This was not a main measure of how well Niktimvo worked in the study.
Median: The number in the middle of a group of numbers lined up from lowest to highest. It's not the same as an average.
Modified Lee Symptom Scale: This measures patient-reported symptom bother using a patient questionnaire. Patients were counted as "less bothered" when they reported an improvement of at least 7 points from the start of the study to week 24.
